相关实验视频
Updated: May 21, 2025
10:28
Body Composition and Metabolic Caging Analysis in High Fat Fed Mice
Published on: May 24, 2018
15.3K
在小鼠中,GLP-2可以预防抗精神病药物诱导的代谢功能障碍
Yanmin Peng1,2, Chenzhang Feng3,4, Shiyu Peng5,6
1Shanghai Key Laboratory of Psychotic Disorders, Brain Health Institute, National Center for Mental Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. ameepeng@gmail.com.
Nature metabolism
|March 21, 2025
概括
类似于葡萄糖类的2类模拟物泰杜格卢提德 (teduglutide) 防止了小鼠的低温和体重增加等抗精神病副作用. 这种激活特定的大脑神经元,为抗精神病药物引起的代谢功能障碍提供了潜在的治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗精神病药物可以引起严重的代谢副作用,包括低温和体重增加.
- 目前针对这些副作用的治疗方法缺乏或对长期管理无效.
研究的目的:
- 为了研究一种类似于葡萄糖类2 (GLP-2) 的类似物 - - 泰杜格卢提德 - - 在减轻抗精神病药物诱导的代谢副作用方面的潜力.
- 阐明这些副作用的潜在神经机制和泰杜格卢的治疗作用.
主要方法:
- 利用小鼠模型来评估 olanzapine (一种抗精神病药物) 和 teduglutide 的作用.
- 通过选择性切除和化学遗传学研究了中腹下丘脑中产诺芬表达神经元 (VMHPdyn神经元) 的作用.
- 测量体温,体重增加,耐葡萄糖和胰岛素敏感性.
主要成果:
- 在小鼠中,特杜格卢提德有效地预防了奥兰扎诱导的低温和体重增加.
- 泰杜格卢提德恢复了葡萄糖耐受性和胰岛素敏感性.
- 奥兰扎抑制了VMHPdyn神经元,而泰杜格类激活了它们;VMHPdyn神经元操纵模仿或逆转奥兰扎的代谢作用.
结论:
- VMHPdyn神经元是抗精神病药物诱导的代谢功能障碍的关键调解者.
- 通过teduglutide进行GLP-2受体激动,代表了一种有前途的治疗策略,以抵消抗精神病药物的急性和慢性代谢副作用.
相关概念视频
01:24Glucagon-like Receptor Agonists
280
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
280
01:23Dipeptidyl Peptidase 4 Inhibitors
148
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
148
01:06Oral Hypoglycemic Agents: Glinides
120
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
120
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
148
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
148